scispace - formally typeset
Search or ask a question

Showing papers by "George L. Mutter published in 2019"

Journal Article•DOI•
Issues in the Differential Diagnosis of Uterine Low-grade Endometrioid Carcinoma, Including Mixed Endometrial Carcinomas: Recommendations From the International Society of Gynecological Pathologists

[...]

Joseph T. Rabban1, C. Blake Gilks2, Anais Malpica3, Xavier Matias-Guiu, Khush Mittal4, George L. Mutter5, Esther Oliva5, Vinita Parkash6, Brigitte M. Ronnett7, Paul N. Staats8, Colin J.R. Stewart9, W. Glenn McCluggage10 •
University of California, San Francisco1, University of British Columbia2, University of Texas MD Anderson Cancer Center3, New York University4, Harvard University5, Yale University6, Johns Hopkins University7, University of Maryland, Baltimore8, King Edward Memorial Hospital9, Belfast Health and Social Care Trust10
01 Jan 2019-International Journal of Gynecological Pathology
TL;DR: This article provides practical recommendations developed from the International Society of Gynecological Pathologists Endometrial Carcinoma Project to address 4 issues that may arise in the diagnosis of uterine corpus low-grade endometrioid carcinoma.
Abstract: This article provides practical recommendations developed from the International Society of Gynecological Pathologists Endometrial Carcinoma Project to address 4 issues that may arise in the diagnosis of uterine corpus low-grade endometrioid carcinoma: (1) The distinction between atypical hyperplasia and low-grade endometrioid carcinoma. (2) The distinction between low-grade endometrioid carcinoma and serous carcinoma. (3) The distinction between corded and hyalinized or spindle cell variants of low-grade endometrioid carcinoma and carcinosarcoma. (4) The diagnostic criteria for mixed endometrial carcinomas, a rare entity that should be diagnosed only after exclusion of a spectrum of tumors including morphologic variants of endometrioid carcinoma, dedifferentiated endometrial carcinoma, carcinosarcoma, and endometrial carcinomas with ambiguous morphology.

42 citations

Journal Article•DOI•
Assessment of a Chemotherapy Response Score (CRS) System for Tubo-Ovarian High-Grade Serous Carcinoma (HGSC).

[...]

Helena M Ditzel1, Kyle C. Strickland2, Kyle C. Strickland1, Emily E. Meserve1, Elizabeth H. Stover3, Panagiotis A. Konstantinopoulos3, Ursula A. Matulonis3, Michael G. Muto1, Joyce F. Liu1, Colleen M. Feltmate1, Neil S. Horowitz1, Ross S. Berkowitz1, Mamta Gupta4, Jonathan L. Hecht4, Douglas I. Lin4, Kirsten Marie Jochumsen, William R. Welch1, Michelle S. Hirsch1, Bradley J. Quade1, Kenneth R. Lee1, Christopher P. Crum1, George L. Mutter1, Marisa R. Nucci1, Brooke E. Howitt5, Brooke E. Howitt1 •
Brigham and Women's Hospital1, Duke University2, Harvard University3, Beth Israel Deaconess Medical Center4, Stanford University5
01 May 2019-International Journal of Gynecological Pathology
TL;DR: A 3-tiered CRS system of hemotoxylin and eosin–stained omental deposits can yield prognostic information for HGSC patients receiving neoadjuvant chemotherapy, and web-based training improved reproducibility but did not alter determination of clinical outcomes.
Abstract: A chemotherapy response score (CRS) system was recently described to assess the histopathologic response and prognosis of patients with tubo-ovarian high-grade serous carcinoma (HGSC) receiving neoadjuvant chemotherapy. The current study was performed as an independent assessment of this CRS system.

30 citations